Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma
AIDS Mar 16, 2018
Rubinstein PG, et al. - The safety of brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (AVD-BV) was investigated in newly diagnosed HIV-associated classical Hodgkin lymphoma. At the recommended phase 2 dose of 1.2 mg/kg, AVD-BV was well-tolerated. It is recommended to avoid concurrent strong CYP3A4 inhibitors.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
